MaxCyte, Washington University in St. Louis announce collaboration

MaxCyte Inc. and Washington University in St. Louis announced a collaboration to develop unique immunotherapy drug candidates based on MaxCyte’s proprietary cell engineering platform technology, CARMA.

CARMA allows simple and rapid manufacture of advanced cancer treatments that utilize a patient’s own immune system and is differentiated from traditional CAR therapy due to its use of mRNA to engineer immune cells delivered back into a patient. By utilizing transient expression via mRNA delivery, CARMA allows control over severe adverse effects, opening the high potency of CAR immunotherapies to a broader range of cancers than traditional CAR approaches.

John DiPersio, chief of the Division of Oncology at Washington University School of Medicine and deputy director of the Siteman Cancer Center, and members of his team will collaborate with MaxCyte to conduct preclinical research with a focus on developing a potential investigational CAR therapy targeting acute myeloid leukemia and other related blood cancers. Financial terms were not disclosed.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Jenna Scott was 29, seven months pregnant, and suddenly, feeling very sick.

July 02, 2026

Vol.52 No.26

By Claire Marie Porter

Obituary

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.

July 02, 2026

Vol.52 No.26

By Paul Goldberg

Clinical Trials & Tribulations

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.

July 02, 2026

Vol.52 No.26

By Paul J. Limburg

Trials & Tribulations

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

AACR urges OMB to retract proposed rule on federally funded research

The American Association for Cancer Research is urging the White House Office of Management and Budget to rescind its recent proposed rule that would give the administration unprecedented political control over government-funded science.

CDC updates ACIP charter

The Centers for Disease Control and Prevention has published an updated version of the charter for the Advisory Committee on Immunization Practices.

July 02, 2026

Vol.52 No.26

By Sara Willa Ernst

MaxCyte, Washington University in St. Louis announce collaboration

YOU MAY BE INTERESTED IN

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

AACR urges OMB to retract proposed rule on federally funded research

CDC updates ACIP charter

Renew today!

Subscriber content

Never miss an issue!

Login

MaxCyte, Washington University in St. Louis announce collaboration

YOU MAY BE INTERESTED IN

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers noteOne woman’s pregnancy shows how this distinction matters

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

Is it time to re-assess the practice and practicality of screening colonoscopy?Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancerNew guidelines offer another option

AACR urges OMB to retract proposed rule on federally funded research

CDC updates ACIP charter

Never miss an issue!

Login

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option